Orili^TM

Indication:
Orili^TM 150 tablet is indicated for the management of moderate to severe endometriosis pain with or without moderate hepatic impairment.
Orili^TM 200 tablet is indicated for the management of moderate to severe pain associated with endometriosis.

Dosage & Administration:
Pregnancy should be excluded before starting treatment with elagolix and start elagolix within 7 days from the onset of menses.
Orili^TM 150 tablet: Initial treatment with Elagolix 150 mg once daily up to 24 months. But, in case of moderate hepatic impairment, up to 6 months treatment is recommended.
Orili^TM 200 tablet: Initial treatment with elagolix 200 mg twice daily up to 6 months (with coexisting dyspareunia). Treatment with elagolix 200 mg should not exist more than 6 months as it may decrease bone mineral density (BMD). In case of moderate to severe hepatic impairment elagolix 200 mg is not recommended.

Preparation:
Orili^TM 150 tablet: Each box contains 12 tablets in Alu-Alu blister pack.
Orili^TM 200 tablet: Each box contains 12 tablets in alu-alu blister strip.